These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16439962)

  • 1. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
    Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
    J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.
    Suzuki H; Wang B; Shivji GM; Toto P; Amerio P; Tomai MA; Miller RL; Sauder DN
    J Invest Dermatol; 2000 Jan; 114(1):135-41. PubMed ID: 10620129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
    Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
    J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity.
    Grabbe S; Steinbrink K; Steinert M; Luger TA; Schwarz T
    J Immunol; 1995 Nov; 155(9):4207-17. PubMed ID: 7594576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
    Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
    J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of systemic immune suppression by UV irradiation in vivo. II. The UV effects on number and morphology of epidermal Langerhans cells and the UV-induced suppression of contact hypersensitivity have different wavelength dependencies.
    Noonan FP; Bucana C; Sauder DN; De Fabo EC
    J Immunol; 1984 May; 132(5):2408-16. PubMed ID: 6232317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultraviolet irradiation of mice reduces the competency of bone marrow-derived CD11c+ cells via an indomethacin-inhibitable pathway.
    Ng RL; Bisley JL; Gorman S; Norval M; Hart PH
    J Immunol; 2010 Dec; 185(12):7207-15. PubMed ID: 21078903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of ultraviolet radiation-induced suppression of contact and delayed hypersensitivity by Aloe barbadensis gel extract.
    Strickland FM; Pelley RP; Kripke ML
    J Invest Dermatol; 1994 Feb; 102(2):197-204. PubMed ID: 7906286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
    Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultraviolet light exposure suppresses contact hypersensitivity by abrogating endothelial intercellular adhesion molecule-1 up-regulation at the elicitation site.
    Komura K; Hasegawa M; Hamaguchi Y; Saito E; Kaburagi Y; Yanaba K; Kawara S; Takehara K; Seki M; Steeber DA; Tedder TF; Sato S
    J Immunol; 2003 Sep; 171(6):2855-62. PubMed ID: 12960307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression.
    Shreedhar V; Giese T; Sung VW; Ullrich SE
    J Immunol; 1998 Apr; 160(8):3783-9. PubMed ID: 9558081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action and other potential roles of an immune response modifier.
    Gaspari AA
    Cutis; 2007 Apr; 79(4 Suppl):36-45. PubMed ID: 17508494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
    Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
    J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
    Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
    J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
    Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
    Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 12 breaks ultraviolet light induced immunosuppression by affecting CD8+ rather than CD4+ T cells.
    Schwarz A; Grabbe S; Mahnke K; Riemann H; Luger TA; Wysocka M; Trinchieri G; Schwarz T
    J Invest Dermatol; 1998 Mar; 110(3):272-6. PubMed ID: 9506448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive effects of photodynamic therapy by topical aminolevulinic acid.
    Hayami J; Okamoto H; Sugihara A; Horio T
    J Dermatol; 2007 May; 34(5):320-7. PubMed ID: 17408441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.